Ertapenem Versus Piperacillin/Tazobactam in the Treatment of Complicated Intraabdominal Infections

Abstract

In this study, the efficacy of ertapenem 1 g once a day was equivalent to piperacillin/tazobactam 3.375 g every 6 hours in the treatment of a range of intraabdominal infections. Ertapenem was generally well tolerated and had a similar safety and tolerability profile to piperacillin/tazobactam. A formal process for review of adequacy of source control was found to be of benefit. The results of this trial suggest that ertapenem may be a useful option that could eliminate the need for combination and/or multidosed antibiotic regimens for the empiric treatment of intraabdominal infections.

Multicenter, Double-Blind, Randomized, Phase II Trial To Assess the Safety and Efficacy of Ceftolozane-Tazobactam plus Metronidazole Compared with Meropenem in Adult Patients with Complicated Intra-Abdominal Infections

“…Although the incidence rates of SAEs (17.1%) and deaths (3.7%) were higher in the ceftolozane-tazobactam group, the overall rates observed in this study are similar to the rates of SAEs (8.9% to 14.0% [24,25]) and deaths (2.5% to 4.9% [24,25,30,31]) that were observed in previous clinical trials of patients with cIAIs. In the current study, shifts in hemoglobin levels were reported more often in the ceftolozane-tazobactam group than in the meropenem group; however, the decreases in hemoglobin levels were not related to the study drug and appeared to be related to complicated surgical procedures in high-risk patients.…”

Phase 2, Randomized, Double-Blind Study of the Efficacy and Safety of Two Dose Regimens of Eravacycline versus Ertapenem for Adult Community-Acquired Complicated Intra-Abdominal Infections

“…This phase 2, randomized, double-blind study compared two dose regimens of eravacycline with ertapenem, a carbapenem antibiotic with demonstrated effectiveness in cIAI (17)(18)(19) and a recommended first-line empirical monotherapy for the treatment of community-acquired cIAIs (1). Eravacycline, at both dose regimens of 1.5 mg/kg q24h and 1.0 mg/kg q12h, had efficacy comparable to that of ertapenem on clinical and microbiological endpoints.…”

Pharmacokinetics of Ertapenem following Intravenous and Subcutaneous Infusions in Patients

“…Ertapenem is a recent long-acting, parenteral carbapenem antibiotic mainly indicated in the treatment of communityacquired infections or hospital-acquired infections without suspicion of Pseudomonas or Acinetobacter (5), as an alternative to penicillin-␤-lactamase inhibitor combination (10,19,23). The pharmacokinetics of ertapenem has been extensively described (2, 3, 6-8, 15, 16, 18, 21).…”